Ryuji Maekawa

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Dendritic cell (DC)-based vaccines relying on several distinct methods for antigen loading have been developed for cancer immunotherapy. 1 In this context, it has been shown that Vγ9 γδ T cells activated by zoledronate can link the innate and adaptive arms of the immune system via DCs so to boost the activation of tumor-associated antigen (TAA)-specific CD8(More)
  • 1